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ASSESSING THE NEW CRITERIA
FOR NEWBORN SCREENING
Jeffrey R. Botkin, MD., MP.H.t
Newborn screening represents the single largest application of
genetic testing in the United States. Through these state-based
programs, newborns are screened for a variety of heritable and
congenital conditions that are not evident at birth by virtue of symp-
toms or clinical examination. Traditionally, the purpose of screening
is early detection or prevention in order to reduce morbidity or mortal-
ity for the child. But as new technologies are developed to conduct
screening, a debate has emerged over whether this traditional justifica-
tion is too narrow. Given the current capability of screening for doz-
ens of conditions, and future capabilities of targeting hundreds more,
should the rationale for screening be expanded to include potential
benefits to parents? More specifically, is a potential benefit to parents
sufficient to justify screening of infants when there is no documented
or anticipated benefit to the child? This paper will summarize this
debate relevant to newborn bloodspot screening that has critical im-
plications for these valuable public health programs.
Newborn screening programs have been run by state health
departments since the 1960's.' The first and paradigm condition for
newborn screening is phenylketonuria or PKU. PKU is caused by a
hereditary defect in the metabolism of a biochemical in food called
phenylalanine. Without dietary treatment, many children with PKU
develop profound mental retardation and severe cognitive damage
often occurs before the condition is clinically evident. Screening at
birth enables the infant to begin a specialized diet within a few weeks
of birth, thus preventing irreparable damage. Newborn screening for
PKU has been a remarkable success. Over the years, state programs
added new conditions to the screening panels, including congenital
hypothyroidism, hemoglobinopathies (including sickle cell disease),
and galactosemia that have been part of most programs for several
t Professor of Pediatrics and Medical Ethics, Associate Vice President for
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1 AAP Newborn Screening Task Force, Serving the Family from Birth to the
Medical Home: Newborn Screening: A Blueprint for the Future A Call for a National
Agenda on State Newborn Screening Programs, 106 PEDIATRIcS 389 (2000).
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decades. However, in the past 5 - 10 years, there has been a rapid
expansion in the number of conditions included on screening panels.2
In large measure, this is due to application of a technology called tan-
dem mass spectrometry. Use of this tool enables screening for dozens
of different conditions simultaneously by analyzing blood spots for
characteristic changes in their biochemical profile. Now a majority of
states screen for more than 30 conditions and some for more than 50.
With this expansion has come a debate over the appropriate criteria
for adding new tests. Is population screening for all of these condi-
tions justified or is this an example of the technological imperative?
An important background element of this discussion is the mode
by which screening is conducted. These are public health programs at
the state level that are mandated by state law in all but 3 places:
Maryland, Wyoming, and the District of Columbia.3 The informed
permission of parents is not sought for screening in other states. In
this regard, newborn screening is markedly different than other forms
of testing, particularly genetic testing, for which informed consent is
considered an important component of testing protocols.4 Parents
may refuse testing on religious or philosophical grounds in most states
but in at least one case, a state has successfully removed a child from
the custody of his parents in order to conduct newborn screening. 5
The original justification for this approach was that the benefits of
screening are so dramatic for conditions like PKU that the state is
within its parens patria authority to mandate screening for newborns.
But if mandatory PKU screening makes sense, does the same logic
hold true for 20, 30 or 50 other conditions? Perhaps if the benefits of
screening are comparable. But the justification for mandatory screen-
ing weakens if the benefits of screening, or the data regarding poten-
tial benefits, are less robust.
2 Bradford L. Therrel & John Adams, Newborn Screening in North Amer-
ica, 30 J. INHERITABLE METABOLIC DISEASE 447, 452 (2007).
3 U.S. GEN. ACCOUNTING OFFICE, NEWBORN SCREENING: CHARACTERISTICS
OF STATE PROGRAMS 22 (2003), www.gao.gov/cgi-bin/getrpt?GAO-03-449 (last
visited Jan. 29, 2009).
4 Nancy Press & Ellen Wright Clayton, Genetics and Public Health:
Informed Consent Beyond the Clinical Encounter, in GENETICS AND PUBLIC HEALTH
IN THE 21ST CENTURY: USING GENETIC INFORMATION TO IMPROVE HEALTH AND
PREVENT DISEASE 505, 516 (Muin J. Khoury et. al. eds., 2000) ("Parents need to be
involved in making choices because they can function better if they know what is
going on and because they bear the consequences most directly when something
adverse happens to their children.").
5 Jenifer Palmer, Omaha Court Case Widens From Screening Test to Baby's
Meals, OMAHA WORLD-HERALD, Oct. 13, 2007, available at http://www.omaha.com/
index.php?u_page=2798&u-sid=10157077.
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I. TRADITIONAL CRITERIA FOR SCREENING
The classic paper on criteria for population screening was pub-
lished by Wilson and Jungner in 1968.6 See Table I. Their criteria
were proposed for the full scope of population screening opportuni-
ties, but their ideas remain particularly important and influential in the
context of newborn screening. Andermann and colleagues recently
published a synthesis of population screening criteria that have
emerged over the past 40 years. 7 Many of the original concepts in the
Wilson and Jungner recommendations were revised to include con-
temporary values including quality assurance, equity, access, and sci-
entific evidence of effectiveness. Nevertheless, the core principles
remain closely aligned over the decades. Many states have developed
their own criteria for their newborn screening programs that often are
based heavily on the traditional Wilson and Jungner criteria. But even
a cursory review of these criteria reveals that they are largely subjec-
tive. For example, what does it mean to say, "[t]he condition sought
should be an important health problem?" If only a few children per
year in a state population die from a preventable condition, does that
constitute an important health problem from our contemporary per-
spective? This subjectivity traditionally led to a wide variation be-
tween states in the conditions targeted by newborn screening.
Although there is more uniformity between states in recent years, for
decades it was the case that some states screened for only 4 - 8 condi-
tions while others screened for more than 20. On this basis alone, it is
clear that while the traditional Wilson and Jungner criteria were
widely adopted in the field, their interpretation has been so broad as to
undermine the notion that meaningful criteria exist at all.
Variation in newborn screening panels is not a feature of US
programs alone. Pollitt recently reviewed screening programs in
Europe and concluded, "[t]here is great variation ... by various bod-
ies in adjacent countries in Western Europe . . This is not due to
the lack of criteria per se but, again, to their subjective nature. Pollitt
notes that the United Kingdom National Screening Committee devel-
oped 19 criteria and it specified 87 items of information that need to
6 j. M. G. WILSON & G. JUNGNER, WORLD HEALTH ORG., PRINCIPLES AND
PRACTICE OF SCREENING FOR DISEASE (1968), available at http://www.who.int/
bulletin/volumes/86/4/07-050112bp.pdf.
7 Anne Andermannet et al., Revisiting Wilson and Jungner in the Genomic
Age: A Review of Screening Criteria Over the Past 40 Years, 86 BULL. OF THE WHO
317(2008).
8 R. J. Pollitt, Introducing New Screens: Why Are We All Doing Different
Things?, 30 J. INHERITED METABOLIC DISEASE 423, 423 (2007).
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be addressed under 35 headings as part of its evaluation of new tests.
In general, European nations screen for substantially fewer conditions
than do most U.S. states. So clearly the struggle to develop justifiable
criteria for this important set of programs is global in scope.
Wilson and Jungner recognized the challenges of screening and
offered this cautionary statement, "[t]he central idea of early disease
detection and treatment is essentially simple. However the path to its
successful achievement ... is far from simple although sometimes it
may appear deceptively easy." Evidence over the intervening years
supports their caution. Screening of populations, or of large popula-
tion groups, often is not effective. On numerous occasions, clinicians
have been enthusiastic about a screening approach and then, as the
data are collected regarding efficacy, the programs are narrowed or
abandoned. For many years, the hospital admission chest X-ray was
routine as a way of detecting occult lung disease, until the evidence
revealed that early detection of diseases like lung cancer was not help-
ful in terms of morbidity or mortality, and the films generated many
alarms and interventions over findings that proved to be benign.
The US Preventive Services Task Force (USPSTF) undertakes a
stringent evidence-based review of a broad range of screening and
testing modalities. A review of their reports illustrates that some
screening approaches appear highly beneficial while there is not clear
evidence of efficacy for many familiar practices. For example, the
USPSTF supports mammography every 1 to 2 years for women over
the age of 40, but finds insufficient evidence to recommend either
clinical breast examination alone or breast self-examination as effec-
tive approaches. 9 In a recent review, it found insufficient evidence to
recommend for or against screening for prostate cancer in men less
than 75 years old and it recommended against screening men older
than 75 years.' 0 The USPSTF also recommends screening for hyper-
tension in adults" and "strongly recommends screening for cervical
9112
cancer in women who have been sexually active and have a cervix.But it found insufficient evidence for screening infants for iron defi-
9 U.S. Preventive Services Task Force, Screening for Breast Cancer,
http://www.ahrq.gov/clinic/3rduspstf/breastcancer/brcanrr.htm (last visited Jan. 11,
2009).
1o U.S. Preventive Services Task Force, Screening for Prostate Cancer,
http://www.ahrq.gov/clinic/uspstfO8/prostate/prostatesum.htm#contents (last visited
Jan. 11, 2009).
11 U.S. Preventive Services Task Force, Screening for High Blood Pressure,
http://www.ahrq.gov/clinic/uspstf/uspshype.htm (last visited Jan. 11, 2009).
12 U.S. Preventive Services Task Force, Screening for Cervical Cancer,
http://www.ahrq.gov/clinic/uspstf/uspscerv.htm (last visited Jan. 11, 2009).
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ciency13 or for elevated lead levels in asymptomatic young children.
1 4
The point is that many screening approaches commonly used by clini-
cians and familiar to the general public are not supported by the data.
Some direct-to-consumer screening methods, such as full body MRI
scans, have virtually no published data at all supporting their utility.
Screening is a very attractive approach to disease prevention. It
seems like it should work but, in fact, the basic mathematics of testing
large numbers of individuals to identify a few treatable cases is very
challenging. Further, screening tests almost always generate numer-
ous "false positive" results that are frightening and often expensive
and risky to address. If the harms from evaluating false positive
results (e.g., tissue biopsies) outweigh the benefits of the program,
then screening programs can be more harmful on balance than no pro-
gram at all. Therefore an effective program requires an accurate, rela-
tively inexpensive screening test, an efficient outreach and engage-
ment effort, and a treatment or prevention strategy that works. It
bears emphasis that a successful program includes more than a good
test and an effective treatment for the condition - it requires that all of
the various elements of a program work together in sequence to
maximize benefits and minimize harms.
Screening programs are not always highly effective even when
good tests and treatments are available. For example, the literature
clearly shows that less than 50% of children identified with sickle cell
disease through newborn screening complied with prophylactic anti-
biotics or the vaccinations that are essential to reduce morbidity and
mortality.15  The screening program provides no direct benefit to
untreated children. In this context, state health departments should
ask whether it is more appropriate to spend limited resources on
13 U.S. Preventive Services Task Force, Screening for Iron Deficiency
Anemia, http://www.ahrq.gov/clinic/uspstf/uspsiron.htm (last visited Jan. 11, 2009).
14 U.S. Preventive Services Task Force, Screening for Elevated Blood Lead
Levels in Children and Pregnant Women, http://www.ahrq.gov/clinic/
uspstf/uspslead.htm (last visited Jan. 11, 2009) (concluding that "evidence is insuffi-
cient to recommend for or against routine screening for elevated blood lead levels in
asymptomatic children aged 1 to 5 who are at increased risk.... [And recommending]
against routine screening for elevated blood lead levels in asymptomatic children
aged 1 to 5 years who are at average risk.").
15 Centers for Disease Control & Prevention, Update: Newborn Screening
for Sickle Cell Disease - California, Illinois, and New York, 1998, 49 MoRBIDITY &
MORTALITY WKLY. REP. 729, 729 (2000); Accord Colin M. Sox et al., Provision of
Pneumococcal Prophylaxis for Publicly Insured Children with Sickle Cell Disease,
290 JAMA 1057, 1061 (2003) (finding that children who should receive prophylaxis
"were dispensed so little prophylactic medication").
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improvements in the sickle cell screening program or use them to add
a new set of screening tests to the panel for which data are scant on
efficacy.
In our era of evidence-based medicine, we should strive for
explicit criteria for each element of a screening program, and we
should gather data before and during the adoption of a new screening
program to assess whether criteria are met. 16 This level of rigor has
not been a part of traditional newborn screening programs.
Evidence-based medicine is becoming increasingly important
given the high cost of US medical care and the recognition that a
substantial portion of clinical care has not been carefully evaluated.
Newer on the block is the evidence-based evaluation of genetic tests.
In the newborn screening context, direct tests of DNA are not widely
utilized, nevertheless, the majority of conditions targeted are genetic
in etiology. Tests generally target changes in biochemistry in the
blood secondary to heritable or congenital conditions. The FDA is not
taking an active role in regulating most genetic tests, enabling compa-
nies to market tests to clinicians and directly to consumers without the
evaluation typical of drugs or devices. An established approach to test
evaluation is captured in the acronym ACCE, standing for Analytic
validity, Clinical validity, Clinical Utility, and Ethical, legal and
social implications.' 7 Analytic validity in the context of newborn
screening testing refers to the ability of the test to correctly character-
ize a target blood sample with known characteristics under typical
laboratory conditions. Clinical validity refers to the ability of the test
to correctly characterize the child as being affected or unaffected with
the condition. Most screening tests are designed to be highly sensitive
but not necessarily highly specific. This means that false positive
results are common and children who receive a false positive result
will need to undergo additional testing to determine whether they are
affected or not. For most newbom screening tests, the ratio of false
positive to true positive results is 10 to 1 or higher so a substantial
portion of the monetary and psychological costs of newborn screening
are created by the need to manage the false positive results.' 8 Clinical
16 Jeffrey R. Botkin, Research for Newborn Screening: Developing a
National Framework, 116 PEDIATRICS 862, 863 (2005).
17 See generally James E. Haddow & Glenn E. Palomaki, ACCE: A Model
Process for Evaluating Data on Emerging Genetic Tests, in HUMAN GENOME
EPIDEMIOLOGY: A ScIENTIFIC FOUNDATION FOR USING GENETIC INFORMATION TO
IMPROVE HEALTH AND PREVENT DISEASE, 217 (Muin J. Khoury et. al. eds., 2004).
18 Beth A. Tarini et al., State Newborn Screening in the Tandem Mass
Spectrometry Era: More Tests, More False-Positive Results, 118 PEDIATRICS 448,
450-54 (2006).
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utility refers to the usefulness of the test results to benefit the individ-
ual tested. Tests can be of high clinical validity but low clinical utility
or vice versa. In the context of NBS, each of the ACCE criteria is
important and these considerations map to the Wilson and Jungner
criteria to a significant extent. For example, Wilson and Jungner state
that there "should be a suitable test or examination." In newer termi-
nology, we would expect a test to have sufficient analytic validity and
clinical validity, although how "sufficient" is defined may vary by test
and condition.
Of the Wilson and Jungner criteria, it is primarily their second cri-
terion that has emerged as the subject of most debate: "There should
be an accepted treatment for patients with recognized disease." In our
context, this means that there should be an established treatment or
preventive intervention for a condition before it is eligible for inclu-
sion on a newborn screening panel. Under the ACCE rubric, we
would say that the test has to have demonstrated clinical utility.
However, this criterion often is misinterpreted as requiring only that
there exist an effective treatment for the condition targeted. In the
context of a screening program, the important criterion is whether
early detection results in improved clinical outcome for the child. If a
treatment can be effectively delivered after clinical diagnosis of a
child, that is, following the development of symptoms, then there is
no rationale for screening of asymptomatic children. Of course, effec-
tive early intervention requires that there be an effective treatment but
the two are not equivalent, Effective treatment is a necessary but not
sufficient criterion for screening. For example, in the adult context,
breast cancer is a treatable condition. Nevertheless, screening is not
appropriate in younger women until the net benefits of early detection
are demonstrated in this group.
II. CRITERIA OF THE AMERICAN COLLEGE
OF MEDICAL GENETICS
In 2004, the American College of Medical Genetics undertook a
project to recommend a uniform panel of conditions for newborn
screening that could be adopted by state programs throughout the
country. 19 This work was commissioned by the Maternal and Child
Health Bureau of the federal Health Resources and Services
Administration (HRSA). The effort involved an evaluation of the
criteria for newborn screening, an analysis of the evidence for a wide
19 Michael S. Watson et al., Newborn Screening: Toward a Uniforn Screen-
ing Panel and System, 8 GENETIcs IN MEDICINE IS, 2S (2006).
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variety of conditions, and recommendations on a uniform panel of
conditions to be targeted by newborn bloodspot screening. The crite-
ria developed can be divided into three main categories: clinical char-
acteristics of the condition, the analytic characteristics of the screen-
ing test, and the diagnosis, treatment and management of the condi-
tion. The working group articulated a number of specific criteria
within these categories and developed a scoring system to rate the
relative fulfillment of each criterion. See Table II. The ACMG work-
ing group then surveyed a total of 289 individuals from a variety of
backgrounds, including experts, clinicians, and consumers, to obtain
scores for each of the 84 conditions under consideration. An expert
panel also conducted a review of the literature to determine whether
there was sufficient evidence to verify the responses of the survey
respondents. The working group recommended 29 conditions for
inclusion on a uniform panel.
Although the ACMG report has been criticized for its methods,2°
the basic criteria are consistent with the Wilson and Jungner tradition.
Newer aspects of the ACMG approach include a strong emphasis on
tests on a multiplex platform. A multiplex platform is one in which
results for multiple conditions are produced from a single analysis. In
the context of newborn screening, this is primarily relevant to a tech-
nology called tandem mass spectrometry (MS/MS) that simultane-
ously analyzes blood for numerous biochemical properties. Therefore
information about dozens of conditions that cause biochemical altera-
tions in blood will be revealed through MS/MS analysis even if the
clinician is only interested in results on a small number of conditions.
In the future, newborn screening may be conducted with another
multiplex platform technology - DNA chips. Screening for one
condition on a chip that contains thousands of genetic markers would
produce results for many genetic markers for which information was
not sought. This produces complex ethical dilemmas when clinicians
are forced to respond to information that may or may not be useful for
the patient.21
20 See Virginia A. Moyer et al., Expanding Newborn Screening: Process,
Policy, and Priorities, HASTINGS CENTER REP., May- June 2008, at 32, 33 (criticizing
the ACMG because "[t]he original ACMG process did not conform to contemporary
standards of evidence-based decision-making"); see also Michael S. Watson et al.,
Newborn Screening: Toward a Uniform Screening Panel and System, 8 GENETICS IN
MEDICINE IS, 2S (2006).
21 See generally Ellen Wright Clayton, Incidental Findings in Genetics
Research Using Archived DNA, 36 J.L. MED. & ETmIcs 286 (2008) (discussing ethical
dilemmas that doctor's face following DNA testing).
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A second but related innovative aspect of the ACMG report is the
emphasis on so-called secondary targets. The working group identi-
fied 25 conditions that fell below the cut-off for inclusion on the
primary core panel but would be conditions identified in the screening
process for the primary conditions. That is, the multiplex platform for
testing identifies an additional 25 conditions that do not, in them-
selves, qualify for screening based on the criteria established. These
additional 25 conditions are, in general, poorly understood and may be
related in some cases to conditions that qualify for inclusion on the
uniform panel. The ACMG working group recommended that state
programs mandate the reporting of all secondary conditions to health
care providers. The net result is that the ACMG recommended that
states mandate a total of 54 conditions for screening on the uniform
panel - 29 core conditions and 25 secondary conditions. The ACMG
did not clearly articulate how states and clinicians are supposed to
manage the complex communication process inherent in the secon-
dary conditions.
The ACMG working group identified opinion and literature that
supported the contention that conditions were amenable to treatment
or amelioration beyond what other groups have been willing to
acknowledge.2 2  It is widely recognized that the literature is very
limited for many rare conditions and there is an almost complete ab-
sence of data from randomized controlled trials of different treatment
modalities. Carefully controlled research is an inherent challenge
with rare conditions because even referral centers will see only a
handful of affected children dispersed over time. Further, even if
there is evidence of an effective treatment, there is little or no
evidence of how a population screening approach works to bring the
benefits of early intervention to affected children and their families.
Finally, there is no consensus on what benefits to children count as
sufficient to justify population screening.
The ACMG approach provides a scoring system for relative bene-
fits ("prevents ALL negative consequences/prevents MOST negative
consequences," etc) but this does not adequately capture the complex-
ity of these conditions. Dionisi-Vici and colleagues note that the
literature suggests that early identification of some organic acidurias
(conditions on the ACMG recommended panel) leads to decreased
early mortality but "[p]rogressive neurocognitive deterioration is
almost invariably present" despite treatment.23 These are devastating
22 See generally Pollitt, supra note 8.
23 Carlo Dionisi-Vici et al., "Classical" Organic Acidurias, Propionic
Aciduria, Methylmalonic Aciduria and Isovaleric Aciduria: Long-term Outcome and
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conditions that are very difficult to manage and children typically
suffer profound neurological impairments. Hypothetically, what if the
evidence shows that screening and early intervention are effective in
delaying the age of serious impairment from 15 months to 30 months?
The magnitudes of these benefits do not approach the benefits of
screening for traditional conditions on screening panels such as PKU,
hypothyroidism, or sickle cell disease. How should these types of
benefits be weighed and judged when making policy decisions? Are
they sufficient to warrant screening of the entire newborn population?
As the ability to detect conditions expands, the debate needs to con-
tinue over whether there is clear evidence of benefit and how much
benefit justifies population screening.
In summary, the rapid expansion in the number of tests on NBS
panels in the US can be attributed to several factors. First, there is the
existence of a new technology, MS/MS, which provides results on a
large number of conditions through a single analysis of a dried blood-
spot. Second, the criteria used to judge candidate conditions for
screening remain highly subjective. Third, there is some evidence
from clinicians that contemporary treatment modalities are effective in
reducing morbidity and/or mortality for these complex conditions.
This information has been extrapolated to conclude that population
screening for such conditions also will be effective. But policy deci-
sions about screening are being made with essentially no evidence
about efficacy derived from studies that actually entail a population
screening approach. Two exceptions are worth noting. Newborn
screening for cystic fibrosis was evaluated through a randomized con-
trolled trial beginning in the 1980's in Wisconsin.24 It has taken ap-
proximately 20 years of follow-up examinations of these children and
other studies to demonstrate that the benefits of screening are suffi-
cient to warrant newborn screening.
A second example is newborn screening for neuroblastoma. This
is an uncommon cancerous tumor of young children that can be
detected through a characteristic pattern of biochemicals in the blood
secreted by the tumor. Despite international enthusiasm for newborn
Effects of Expanded Newborn Screening Using Tandem Mass Spectrometry. 29 J.
INHERITED METABOLIC DISEASE 383, 383 (2006).
24 Philip M. Farrell et al., Early Diagnosis of Cystic Fibrosis Through Neo-
natal Screening Prevents Severe Malnutrition and Improves Long-Term Growth, 107
PEDIATRICS 1 (2001).
25 See Scott D. Grosse et al., Newborn Screening for Cystic Fibrosis: Evalua-
tion of Benefits and Risks and Recommendations for State Newborn Screening
Programs, MORBIDITY & MORTALITY WKLY. REP.: RECOMMENDATIONS & REP., Oct.
15, 2004, at I passim.
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screening, two carefully designed trials of screening failed to show
any benefit from early detection.26 Neuroblastoma was a condition
that appeared ideal for NBS prior to the actual evidence. This experi-
ence has not inhibited policy makers from using "colloquial evidence"
in the ACMG report for decisions to rapidly expand newborn screen-
ing panels.5
This discussion illustrates that there is substantial work to be done
on the articulation of criteria for newborn screening even under tradi-
tional approaches where direct benefit to the child is a primary objec-
tive. What does benefit to the child mean? How much benefit is
enough to justify population screening in light of the risks of screen-
ing and the opportunity costs? How much evidence is sufficient to
initiate a new program? In conjunction with these long-standing
complexities, new, alternative criteria for newborn screening are
under active consideration.
III. NEW CRITERIA FOR SCREENING
The emerging debate is focused on the question of whether
screening might be justified even when benefits to the child are
entirely unproven or unexpected. Dwayne Alexander, Chief of the
Eunice Shriver National Institute for Child Health and Development
at the NIH, and Peter van Dyke, Chief of HRSA, advocate a change in
thinking about the criteria for newborn screening: "With the potential
of greatly expanded testing, many have begun to question one stan-
dard tenet of newborn screening.. . that it's appropriate to screen only
for conditions for which an effective treatment already exists.27 The
tenet served a useful purpose in early years, but it's now being chal-
lenged as outmoded, because it fails to consider other benefits." Con-
tinuing on in that same article, they state: "The technology could be
expanded to screen for additional disorders as mutational analysis or
other multiplex technology becomes available, with decisions being
based more on what not to screen for (perhaps Huntington disease)
than on what to include." Alexander and van Dyke suggest a future
world in which we might have an extraordinarily large number of tests
on NBS panels, due in large measure to the technical ability to detect
26 William G. Woods et al., Screening of Infants and Mortality Due to
Neuroblastoma, 346 NEW ENG. J. MED. 1041. 1045 (2002) ("It is more likely that
screening has no effect on mortality due to neuroblastoma."); Freimut H. Schilling et
al., Neuroblastoma Screening at One Year of Age, 346 NEW ENG. J. MED. 1047, 1052
(2002) ("Our findings do not support mass screening for neuroblastoma at one year of
age.").
27 Duane Alexander & Peter C. van Dyck, A Vision of the Future of Newborn
Screening, 117 Pediatrics S350, S352 (2006).
HEALTH M4TRIX
those conditions in blood spots and a potential change in attitude
about the necessary criteria for screening.
What are the other benefits beyond those to the child directly that
might be considered? There are four types of benefits that are pro-
posed: 1) elimination of the "diagnostic odyssey," 2) the provision of
reproductive risk information to parents, 3) fostering research with
affected children, and 4) the developmental, psychological, and social
benefits that occur from early disease detection. Bailey and col-
leagues have been articulate advocates of the fourth type of benefit in
the context of children with conditions causing mental retardation or
developmental delay.28 They argue that, even in the absence of defini-
tive treatments for many conditions associated with mental retardation
and developmental delay, early intervention can lead to improved
developmental and behavioral outcomes. Further, families benefit
from the expanded availability of services and research about the con-
ditions is fostered. I mention this fourth type of benefit first only to
say that it is not different from traditional criteria. If early interven-
tion leads to improved developmental outcomes, then those benefits
are no different than benefits that might accrue from drug or dietary
treatments that are tailored to the disease. These are potential benefits
directly to the child and if they occur through early detection from a
screening program, then such benefits are consistent with traditional
criteria. Caveats here are that the benefits that occur through early
intervention must still outweigh the potential harms and other costs of
the screening program. Further, as noted above, the benefits from
early intervention through screening must be greater than the benefits
of interventions initiated following clinical detection of the condition.
Third, the early interventions that provide benefit must be available
and used by a meaningful number of the children detected through a
screening program. All of these caveats are relevant to any treatment
or prevention strategy employed after newborn screening. It should
not be sufficient to demonstrate that early intervention is effective in
selected groups under controlled study conditions - such benefits
should be demonstrated in the "real world" through pilot studies of
population screening for such conditions.
A. Eliminating the Diagnostic Odyssey
One central feature of newborn screening is the identification of
children at birth rather than at an older age when symptoms develop.
28 Donald B. Bailey Jr., Debra Skinner, & Steven F. Warren, Newborn
Screening for Developmental Disabilities: Reframing Presumptive Benefit, 95 Am. J.
PuB. HEALTH 1889, 1889 (2005).
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Many of the conditions targeted by newborn screening are metabolic
disorders that tend to present clinically with vague or non-specific
symptoms like vomiting, irritability, or lethargy. Symptoms may be
episodic so that care providers may not see the child when the mani-
festations are the worst. The rare nature of the conditions also makes
it challenging for clinicians to quickly identify the disease. Many
parents of affected children report that it took months or years for
physicians to make the correct diagnosis, perhaps with many struggles
and journeys along the way as parents become increasingly frustrated
and frantic for answers. For example, a diagnosis of Duchenne
Muscular Dystrophy (DMD) typically is made 2 years after symptoms
of weakness are first noted by parents.2 9 DMD has been included on a
few state and national NBS panels but is not on the ACMG panel. It
represents a condition for which screening is possible but no early
interventions exist that change the course of the disease. In a
Colorado study, the diagnosis of cystic fibrosis (CF) without newborn
screening was delayed to an average of 14.5 months without newborn
screening.3°
There is no question that the diagnostic odyssey is an extremely
difficult experience for parents and family members, as well as for
clinicians. And it is highly likely that elimination of this odyssey
would be a net benefit to the parents of affected children although this
has not been well studied through prospective randomized trials. The
existing literature for conditions like CF suggests that parents experi-
ence considerable burdens through a delay in diagnosis.31 One coun-
tervailing concern is the loss of the period of time when parents
believe their child is healthy. This might be considered a time of
blissful ignorance before worrisome symptoms develop. While this
phenomenon also needs to be better studied, any adverse conse-
quences of this loss of innocence are likely to pale in contrast to the
difficulties parents face in coming to a correct diagnosis.
Baily and Murray also wonder whether early diagnosis in the
absence of effective treatments leads to a therapeutic odyssey.32 That
29 Lainie Friedman Ross, Screening for Conditions That Do Not Meet the
Wilson and Jungner Criteria: The Case of Duchenne Muscular Dystrophy, 140A AM.
J. MED. GENETICS 914, 915-16 (2006).
30 Frank J. Accurso, Marci K. Sontag, & Jeffrey S. Wagener, Complications
Associated with Symptomatic Diagnosis in Infants with Cystic Fibrosis, 147 J.
PEDIATRICS S37, S38-S39 (2005).
31 See Philip M. Farrell et al. Bronchopulmonary Disease in Children with
Cystic Fibrosis After Early or Delayed Diagnosis, 168 AM. J. RESPIRATORY &
CRITCAL CARE MED. 1100 (2003).
32 Mary Ann Baily & Thomas H. Murray, Ethics, Evidence, and Cost in
Newborn Screening: Would Resources Spent on Screening be Better Spent Else-
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is, perhaps parents in this circumstance search the web and travel from
one practitioner to another, wherever some hope is offered. If so,
elimination of the diagnostic odyssey would be of little benefit to
parents who would still be searching for an answer for their child.
Benefits from elimination of the diagnostic odyssey are in propor-
tion to the typical delays in clinical diagnosis. If clinicians were more
astute, or had algorithms in place to do targeted screening on children
with early suggestive symptoms, the diagnostic odyssey could be
reduced or eliminated. Targeted screening is a common approach
when a subgroup of the population can be identified that is at
increased risk for the disease. Mammography is recommended for
older women, not all women, because the incidence of breast cancer is
substantially higher in older women and the test is more sensitive.
Even though missed cases of breast and colon cancer are among the
top reasons for malpractice suits for internists, full population screen-
ing has not been justified on this basis. Unfortunately, the debate over
newborn screening has not prompted any significant discussion of
alternatives to population screening. Targeted screening approaches
should be carefully considered for some conditions before the diag-
nostic odyssey is promoted as a partial justification for NBS.
The question in this context is how much weight to give to elimi-
nation of the diagnostic odyssey in policy decisions about NBS. I will
raise two points here for further elaboration below. First, screening is
not risk free. Many parents will be told their child has an abnormal
laboratory test and needs further evaluation only to learn that the
initial test was a false positive. This is an expected outcome of all
screening programs for rare or uncommon conditions. Further, we
know that a subset of parents will experience negative repercussions
from false positive results that can persist long after the parents are
told the child is healthy. In the context of a condition for which there
is no treatment, the benefits of an elimination of the diagnostic odys-
sey for parents of affected children must be weighed against the nega-
tive impacts of receiving false positive results or ambiguous
results on a larger group of parents.
The second consideration is that NBS is conducted without paren-
tal permission in all but two states (Maryland and Wyoming) and the
District of Columbia. As noted, the traditional justification for man-
dating newborn screening is that the benefits to the child are so
substantial that the state can override parental authority regarding
testing. If the rationale for screening is the elimination of the diagnos-
tic odyssey for parents, the justification for mandatory screening of
where?, 38 HASTINGS CENTER REP.23, 28-29 (2008).
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the child cannot be sustained. For these reasons, elimination of the
diagnostic odyssey is an important but secondary benefit of NBS. It
should not be considered a primary justification for mandatory popu-
lation screening.
B. Reproductive Information for Parents
Most of the conditions targeted by NBS are genetic in etiology
and most exhibit an autosomal recessive pattern of inheritance. For
recessive conditions, each parent is a carrier of a mutation and both
parents must contribute a mutated copy of the gene to produce a child
with the condition. Each pregnancy of two such carriers has a 25%
chance of resulting in an affected child. One hallmark of conditions
potentially appropriate for newborn screening is that the conditions
are not evident at birth. Without screening, the correct diagnosis may
be delayed for months or years. In the meantime, the parents may
have additional affected children. Therefore, a potential advantage of
newborn screening is that parents are alerted to their reproductive risk
prior to the birth of a second affected child.
While theoretically attractive, the magnitude of this benefit is un-
clear in the US population. A benefit would consist of sufficient
information to allow a decision that parents would not have made
otherwise. In this context, this means either deciding not to have ad-
ditional children after the first affected child, or using prenatal diag-
nosis and pregnancy termination in the event of an affected fetus. A
study in Australia published in 2000 indicated that two thirds of par-
ents of children with CF detected through newborn screening had ad-
ditional children and two thirds of those chose to have prenatal diag-
nosis for CF.33 Many of those who did not have additional pregnan-
cies indicated that the possibility of an additional affected child was a
significant reason. Of those pursuing prenatal diagnosis, the majority
either terminated an affected pregnancy or said they would do so. The
US experience may be somewhat different. Mischler et al. found in a
1998 study of parents of children with CF identified through NBS that
70% of families had additional children, 26% of those families util-
ized prenatal diagnosis, but none of the 3 affected pregnancies were
terminated.34
33 Tracy Dudding et al., Reproductive Decisions After Neonatal Screening
Identifies Cystic Fibrosis, 82 ARCHIVES DISEASE CHILDHOOD FETAL NEONATAL
EDITION F 124, F 125 (2000).
34 Elaine H. Mischler et al., Cystic Fibrosis Newborn Screening: Impact on
Reproductive Behavior and Implications for Genetic Counseling, 102 PEDIATRICS 44,
44(1998).
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Overall, the data are limited on the behavioral responses of par-
ents to reproductive information provided through newborn screening.
We would expect responses to be influenced by the severity of the
condition, the availability of counseling services and prenatal diagno-
sis, and cultural values. It is probably fair to conclude that NBS pro-
vides valuable information for many parents about reproductive risk
and that many parents utilize this information for making reproductive
decisions.
The relevant question for our purposes is the weight to be
afforded this potential benefit of newborn screening. One significant
disadvantage of providing reproductive risk information through NBS
is that this requires one affected child to be born before parents are
alerted to their risk. If risk detection is a priority, then carrier detec-
tion in adults prior to pregnancy or during pregnancy would be more
timely. The American College of Obstetrics and Gynecology recom-
mended that carrier identification for CF and hemoglobinopathies be
offered to adults with at-risk heritage prior to or during pregnancy.
35
Currently rates of carrier testing during pregnancy for these conditions
are not consistently high due both to inconsistent offers by clinicians
and limited demand by couples. In the future, the need for newborn
screening may decline if prenatal carrier screening followed by prena-
tal diagnosis for conditions like CF is utilized by a high proportion of
the population.36 Why screen every newborn if most parents know the
status of their fetus before delivery?
For most other hereditary conditions targeted by newborn screen-
ing programs, there has not been a concerted effort to develop prenatal
screening approaches. There are significant technical challenges in
this regard. As noted, newborn screening technologies often work by
identifying an abnormal accumulation of biochemicals in the infant's
bloodstream. This approach generally is not useful for the detection
of unaffected adult carriers before or during pregnancy because carri-
ers do not have the same accumulation of biochemicals as affected
individuals. If screening moves to a DNA-based platform, then prena-
tal screening of couples for the same conditions targeted by newborn
screening may become feasible. Technical challenges aside, many
couples who would not terminate a pregnancy will decline prenatal
diagnosis with the knowledge that affected children will be identified
35 American College of Obstetricians and Gynecologists Committee on Ge-
netics, Update on Carrier Screening for Cysstic Fibrosis, 106 OBSTETRICS &
GYNECOLOGY 1465 (2005).
36 Bridget Wilcken, Letter to the Editor, Community-Wide Screening for
Cystic Fibrosis Carriers Could Replace Newborn Screening for the Diagnosis of
Cystic Fibrosis, 44 J. PAEDIATRICS & CHILD HEALTH 232,232 (2008).
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at birth through NBS. Therefore, while there is some overlap between
prenatal and neonatal screening, newborn screening will not be
replaced by prenatal screening and diagnosis in the foreseeable future.
From an ethical perspective, providing genetic information rele-
vant to the parents by testing their children raises obvious concerns.
This discussion has focused on reproductive information but note that
the same rationale could be offered for other types of genetic testing.
Newborn screening is relatively efficient because it captures almost
all babies in the population through well-established programs. If
genetic testing for risk of, say, colon cancer is beneficial for adults, as
the current literature suggests, why not screen infants for the relevant
genes in order to detect at-risk parents? Our answer since the advent
of modern genetic testing hinges on the recognition that genetic test-
ing often provides information that has a powerful impact on indi-
viduals for both good and bad. The literature clearly shows that many
adults do not want predictive genetic testing. Therefore genetic test-
ing generally should be conducted only with the informed consent of
the individual being tested, or their parents in the case of pediatric
testing. Newborn screening has been an exception to this rule. But in
a situation where testing provides a significant benefit to the parents
rather than the child, the parents themselves should consent to testing.
In the case of adult onset diseases like colon cancer, genetic testing
should be offered to adults themselves and provided with their
informed consent even though this may be less efficient than screen-
ing all newborns on their behalf. The efficiency of testing newborns
for the benefit of their parents does not justify this backdoor approach.
Similarly with respect to reproductive information for parents, manda-
tory newborn screening is not ethically appropriate when parents
could be tested directly or asked their consent for screening of their
child for information relevant to their future pregnancies.
Traditionally, the provision of reproductive risk information to
parents has been considered a secondary benefit of NBS. That is, it
has been considered an important benefit but not one that alone justi-
fies newborn screening. Those who are the most forceful advocates of
expanded newborn screening are not arguing otherwise. The new
question is whether a number of these secondary benefits together are
sufficient to justify screening in the absence of an anticipated benefit
to the child. As we have seen, justification by the accumulation of
secondary benefits is stymied by the lack of informed permission for
newborn screening.
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C. Research Promotion
The fourth proposed justification for newborn screening in the
absence of clear benefit to the child is the value screening programs
provide for the understanding of rare conditions. Research on many
conditions potentially amenable to newborn screening is extremely
difficult due to their low prevalence in the population. This means
that even the most senior expert in the field will have only limited
experience with any one condition. Research on the best available
treatments will be frustrated by the inability to recruit enough children
in the same time frame to compare competing approaches. Further,
medical technology changes over time so it is difficult to know
whether the outcomes of children evaluated with a condition in, say,
the 1980s are still relevant to children with the condition today.
Inclusion of such rare conditions on screening programs provides
a number of opportunities to better understand the diseases. First and
foremost, affected children are identified shortly following birth using
relatively consistent case definitions. These cases can be identified
through health department records rather than through the records of
health providers scattered throughout the health care system. Follow-
ing these children from birth provides the chance to understand the
natural history of the disease, or the course of the disease under the
different treatment modalities commonly used. Second, screening
identifies children across the range of severity of the condition. Often
rare diseases are characterized by the signs and symptoms of indi-
viduals who are the most severely affected. These are the people who
come to clinical attention most readily. However, many conditions
exhibit a wide range of severity, including individuals who are so
mildly affected that they would not be clinically identified through
symptoms alone. Screening the entire population identifies these mild
cases as well as the more classic cases. This can be a significant
benefit to those trying to understand the condition and to those who
might otherwise go undiagnosed with a treatable condition. But it
also can be burden to some individuals who are labeled as "having a
disease" despite having such a mild form that they were never
destined to be ill. Screening programs can identify many more indi-
viduals who are affected with a condition in a population than were
recognized prior to screening.37 A third advantage of screening from
a research perspective is that enough children can be identified across
37 Bridget Wilcken et al., Screening Newborns for Inborn Errors of Metabo-
lism by Tandem Mass Spectrometry, 348 NEw ENG. J. MED. 2304,2308 (2003).
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the population to enable recruitment into clinical trials to formally test
new treatments.
All of these potential advantages provided by screening with re-
spect to research are unassailable, except for the fact that the research
infrastructure does not currently exist to realize such benefits. There
is no national registry or system in place to acquire data on children
with conditions identified through NBS, nor systems to enable
recruitment into controlled trials. Children are being identified with
these rare conditions but for the most part the clinical data remains
locked within their medical records in offices scattered across the
country. Currently the Eunice Shriver National Institute for Child
Health and Development at the NIH is planning a national network of
research centers that may provide exactly this type of research support
for newborn screening. But this network will not be in place for sev-
eral years. Therefore it is disingenuous to argue that new newborn
screening tests are justified today based on the opportunities for
research. Efforts to develop such an infrastructure should take prior-
ity over the expansion of NBS to include conditions for which there is
not clear evidence of benefit to the children.7
IV. THE COSTS AND RISKS OF
NEWBORN SCREENING
Policy decisions need to be made in the light of a full assessment
of the benefits, costs, and risks of the options available. This discus-
sion has focused on the various benefits potentially provided by new-
born screening. The risks of NBS are primarily two-fold: false posi-
tive results and results of unknown clinical significance. False posi-
tive results occur with every screening program due to the inability of
any test in a human system to function flawlessly. Tests will have a
sensitivity that is less than 100% (the ability to identify those with the
condition) and a specificity that is less than 100% (the ability to iden-
tify those without the condition). When the specificity of a test is not
perfect, an unaffected individual will occasionally produce a positive
test result - a false positive. Initial positive screening tests are usually
followed by additional testing to separate the true positive from the
false positive results. For uncommon conditions, it is typical for a test
to yield 10 to 50 false positive results for every true positive. That is,
the "positive predictive value" of newborn screening tests are 10% or
less. Again, this is a feature of virtually all screening programs and is
not due to any particular limitation of tests in the context of newborn
screening.
Much of the cost of many screening programs arises from the
need to contact individuals with initial positive screens and conduct
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confirmatory testing. But the cost of false positive results is not the
primary concern. The primary concern is the psychological impacts
of this frightening information. Parents are understandably alarmed
when they are initially informed that the newborn screening test is
positive. For some parents, the distress this causes does not resolve
completely when further testing determines that the child is healthy.
A substantial number of parents will have residual anxiety about the
health of their child that can last months or years. 19
As noted, false positive results are an expected outcome of screen-
ing programs and it is incumbent on programs to reduce the burden of
this phenomenon by maximizing the quality of the tests and by pro-
viding results in a sensitive, timely and accurate manner. The point of
this discussion is that the relative burden of false positive results
looms larger as the benefits of screening grow smaller. For programs
like PKU screening, the benefits to the affected children far outweigh
the burdens to parents who initially receive false positive results. But
when screening provides limited or no benefits to the child, it is pos-
sible for the burdens of the screening program to outweigh the bene-
fits. If the benefits of screening are primarily the secondary benefits
of a reduction in the diagnostic odyssey, the provision of reproductive
information for parents, and the promotion of research opportunities,
it is quite possible that policy makers would consider the burdens of
false positive results to be excessive and not justifiable.
A second risk of screening programs is the identification of indi-
viduals with mild versions of the condition or versions of unknown
clinical significance. The severity of many conditions exists along a
broad spectrum. This is due to the fact that mutations in genes associ-
ated with these diseases may reduce the function of the gene by vari-
able amounts. There also may be other genes or environmental fac-
tors that can exacerbate or ameliorate the condition. Occasionally
benign conditions can mimic more severe diseases on the test results.
This was a poorly understood phenomenon during the early years of
PKU screening. Hyperphenylalaninemia is a condition that looks like
PKU on the initial test result but does not lead to mental retardation.
But if children with hyperphenylalaninemia are treated with the
dietary restrictions appropriate for PKU, they can suffer significant
harm. When rare conditions are poorly understood, infants with
benign or mild variants may not be distinguishable from infants with
more severe variants, and if they are treated aggressively on the
assumption that they are classic cases of severe disease, they may be
harmed as a result.
The broader point is that screening programs may have significant
negative impacts on some individuals due to false positive results and
due to the stigma and overtreatment of individuals with benign or
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mild variants of the condition. These are unfortunate outcomes to be
minimized but tolerated when screening provides substantial benefits
to those affected with the disease. But when the benefits of screening
are unsubstantiated, these potential negative impacts demand great
caution in the introduction of new screening modalities. When there
are no benefits of screening to the affected child, then these negative
impacts may outweigh the benefits to parents through the elimination
of the diagnostic odyssey, the provision of reproductive information,
and/or the promotion of research.
The final harms or costs to newborn screening programs are the
opportunity costs. As we have seen, well-established screening
programs like sickle cell disease function at partial efficiency. Public
health programs in the US are poorly funded in many states. Given
this situation, more lives may be saved by devoting full attention and
resources to programs that we know can be effective rather than add-
ing more and more tests for poorly understood conditions. It also is
worth emphasis that the US ranks about 29th in the developed world
for infant mortality.38 This ranking is not due to the relative absence
of newborn screening tests where the US ranks at or near the top.
Pouring additional resources and expertise into NBS will not improve
this ranking. Again, should health departments be marshalling re-
sources to progressively expand newborn screening, or should these
resources be spent in other, more productive areas for the welfare of
children?
V. CONCLUSIONS
Newborn screening programs impact every child born in the US
and in the developed world. Accordingly, the discussion of criteria
for screening should engage a wide spectrum of experts, scholars,
advocates and lay individuals. But the analyses and opinions of these
debaters are only as good as the data on which policy decisions must
be made. Without a better understanding of all of the hypothetical
benefits and risks discussed above, debates will continue endlessly as
either worthless programs proliferate or valuable programs are sty-
mied. The first priority must be the creation of a research infra-
structure that will enable the pilot introduction of new tests with the
accumulation of data to define efficacy, and to identify weak elements
in programs that prove to be partially effective. A central criterion for
38 NAT'L CTR. FOR HEALTH STATISTICS, HEALTH, UNITED STATES, 2007 wrrH
CHARTBOOK ON TRENDS IN THE HEALTH OF AMERICANS 172 (2007) available at
http://www.cdc.gov/nchs/data/hus/hus07.pdf.
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the inclusion of new tests must be that sufficient data exist on which
to make an informed decision about population screening.
With respect to the newer criteria discussed above, the challenge
of moving from a status as a secondary criterion to a primary criterion
is the absence of informed consent. Benefits afforded to parents do
not justify mandatory screening of their children. If we wish to pro-
mote these benefits to parents as sufficient for screening, then this
must be done in a context of an offer of screening to parents who will
make an informed choice. If we value the efficiency of a mandatory
approach to screening, then substantial benefit to the child must
remain a central criterion for new programs.
TABLE I. WILSON AND JUNGNER SCREENING
CRITERIA
1. The condition sought should be an important health problem
2. There should be an acceptable treatment for patients with rec-
ognized disease
3. Facilities for diagnosis and treatment should be available
4. There should be a recognizable latent or early symptomatic
stage
5. There should be a suitable test or examination
6. The test should be acceptable to the population
7. The natural history of the condition, including development
from laten to declared disease, should be adequately understood
8. There should be an agreed policy on whom to treat as patients
9. The cost of case-finding(including diagnosis and treatment of
patients diagnosed) should be economically balanced in relation to
possible expenditure on medical care as a whole
10.Case-finding should be a continuing process and not a "once
and for all" project
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TABLE II: ACMG CRITERIA FOR NEWBORN
SCREENING
>1:5,000 100
>1:25,000 75
Incidence of Condition >1:50,000 50
>1:75,000 25
<1:100,000 0
Never 100
Signs & Symptoms clini- <25% of cases 75
cally identifiable in the fist <50% of cases 50
48 hours <75% of cases 25
Always 0
Burden of disease if un- Profound 100
treated Severe 75
Moderate 50
(Natural history if un- Mild 25
treated) Minimal 0
Does a sensitive AND YES 200
specific screening test cur- NO 0
rently exist?
Doable in neonatal blood spots
OR by a simple, in nursery 100
physical method
High Throughput 50
(>200/day/FTE)
Test Characteristics Overall analytical cost < 1$ per 50(Yes = apply score test per conditionNo = zero) Multiple analytes relevant to
one condition are detected 50
in same run
Other conditions identified 50
by same analytes
Multiple conditions detected by 200
same test (multiplex platform)
Treatment exists and is widely 50
available in most communities
Availability of treatment Treatment exists but availability 25
is limited
No treatment available 0
or necessary
Inexpensive 50
Cost of treatment Expensive 0
(>$50,000/patient/year)
To prevent ALL negative conse- 200
quences
Potential efficacy of To prevent MOST negative 100
existing treatment consequencesTo prevent SOME negative 50
consequences
Treatment efficacy not proven 0
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Clear scientific evidence that
intervention resulting from 200
Benefits of early screening optimize outcomeieetiof eaSome scientific evidence that
intervention
(INDIVIDUAL early intervention resulting from 100OUTCOME) screening optimizes outcomeNo scientific evidence that early
intervention resulting from 0
screening optimizes outcome
Early identification maximizes
benefits (education, understand-
Benefits of early ing prevalence and natural
identification history, cost effectiveness)
(FAMILY & SOCIETY) Early intervention improves 50
benefits
No evidence of benefits 0
Early diagnosis and treat- YES 100
ment prevent mortality NO 0
Providers of diagnostic confirma- 100
tion are widely available
Diagnostic Confirmation Limited availability of providers 50
of diagnostic confirmation
Diagnostic confirmation is
available only in a few centers 0
Providers of acute management 100
are widely available
Clinical management Limited availability of providers 50
of acute management
Acute management is available 0
only in a few centers
Management at the primary care 200
or family level
Simplicity of therapy Requires periodic involvement of 100
a specialist 100
Requires regular involvement of 0
a specialist
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